Sunstone leads €8.7m Prexton Therapeutics round

Previous investor MS Ventures also took part in the round.

Prexton will use the funding to bring its therapy for the improvement of motor complications in Parkinson's disease patients to phase-1 trials.

Sunstone Capital is a pan-European venture capital investor with a focus on early-stage life science and technology companies. Ysios Capital is a Spanish venture firm that invests in early- to mid-stage human healthcare and life sciences companies. It is currently raising its second fund, which is targeting €100m.

Company
Founded in 2012 by François Conquet and MS Ventures as a spin-off of Darmstadt-based pharmaceutical company Merck Serono, Prexton focuses on treatments for Parkinson's disease and other brain disorders. The company is based in Geneva.

People
Jasper Bos is a senior director at MS Ventures. François Conquet is CEO of Prexton Therapeutics. Raúl Martín-Ruiz is an investment director at Ysios Capital and Andreas Segerros is a partner at Sunstone Capital. Both will take seats on the board of directors at Prexton.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Switzerland
• Sunstone Capital A/S